Monday, November 24, 2025




In Detail Full day, Monday, November 24, 2025, Timezone: America/Chicago


FDA Approves Pembrolizumab + Enfortumab Vedotin-ejfv for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer / OncoDaily

oncodaily - What Does FDA Approval Mean? The U.S. Food and Drug Administration (FDA) evaluates new cancer therapies to determine whether they are safe and effective for clinical use. Approval is based […]

#healthcare #pharmaceuticals #publichealth #drugdevelopment #fda


Monday, November 24, 2025, 10:23 am / permalink 16257 / 2 stories in 3 months


M. Tezer Kutluk: 2025 Update of World Cancer Declaration with UICC Board / OncoDaily

oncodaily - M. Tezer Kutluk, Professor of Pediatrics and Pediatric Oncologists, Chair of the Scientific Board at Medicana Health Group, shared a post on LinkedIn: “Dear friends, Between 18–20 November 2025 in Melbourne, […]

#healthcare #publichealth


Geriatric Oncology Updates


Global Cancer Leadership & Policy


Innovative Cancer Treatment & Research


Other Cancer & Related Topics


Monday, November 24, 2025, 4:21 am / permalink 16241 / 47 stories in 3 months


StackHealth Time Machine




Outgoing Stories


Judge orders Leapfrog to remove safety grades for five Florida hospitals 3 stories in 22.8 hours

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis 4 stories in 41.8 hours

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity 6 stories in 55.8 hours

White House briefing triggered rapid drops in acetaminophen use in ERs 2 stories in 59.8 hours

MUSC Health buys large South Carolina multispecialty practice for $111M 4 stories in 59.8 hours

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage 19 stories in 84.9 hours

Analysis finds small patient group drives majority of admissions and costs 3 stories in 84.9 hours

Springing forward worsens sleep and sparks health complaints 8 stories in 88.9 hours

Cancer Grand Challenges awards five teams bold funding for cancer research 67 stories in 95.9 hours

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes 3 stories in 97.9 hours


More StackHealth


Bluesky:



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.